Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
UNMET THERAPEUTIC NEEDS IN THE MANAGEMENT OF ACUTE-ISCHEMIA
Autore:
WHITE HD;
Indirizzi:
GREEN LANE HOSP,DEPT CARDIOL,PRIVATE BAG 92 189 AUCKLAND 1030 NEW ZEALAND
Titolo Testata:
The American journal of cardiology
fascicolo: 4A, volume: 80, anno: 1997,
pagine: 2 - 10
SICI:
0002-9149(1997)80:4A<2:UTNITM>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; PLATELET GLYCOPROTEIN IIB/IIIA; CORONARY-ARTERY DISEASE; NON-Q-WAVE; UNSTABLE ANGINA; THROMBOLYTIC THERAPY; HEART-DISEASE; ATHEROSCLEROTIC PLAQUES; INTEGRIN RECEPTOR; BYPASS-SURGERY;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
63
Recensione:
Indirizzi per estratti:
Citazione:
H.D. White, "UNMET THERAPEUTIC NEEDS IN THE MANAGEMENT OF ACUTE-ISCHEMIA", The American journal of cardiology, 80(4A), 1997, pp. 2-10

Abstract

Unstable angina and myocardial infarction (MI) continue to present a major challenge in clinical management, These acute ischemic coronary syndromes (AICS) are a spectrum of clinical presentations of the same pathophysiologic mechanism: thrombus formation superimposed on atherosclerotic plaque disruption or erosion, Current approaches to the management of AICS, which include both interventional and pharmacologic therapy, have been introduced to clinical practice during the past 20 years, and most of them have demonstrated efficacy in clinical studies, Acommon inadequacy of current therapies, however, is the lack of significant inhibition of platelet aggregation - the crucial event in the formation of coronary thrombi and the pathogenesis of AICS, The final common pathway to platelet aggregation is the activation of the platelet glycoprotein (GP) IIb-IIIa receptor, which allows the cross-linking of adjacent platelets by the adhesive plasma proteins fibrinogen and van Willebrand's factor. The emergence of the GP IIb-IIIa receptor as apotential treatment target has led to the development of several inhibitors of its function, The inhibitors most advanced in clinical development are the chimeric monoclonal antibody abciximab (ReoPro) and thecyclic peptide eptifibatide (INTEGRILIN), In phase III clinical trials, both abciximab and eptifibatide have been shown to reduce the Incidence of cardiac events in patients at risk for abrupt vessel closure after coronary angioplasty, Inhibition of the GP IIb-IIIa receptor is the most promising novel approach to the treatment of unstable angina and MI, and if may soon be an indispensable component of the managementof patients with AICS. (C) 1997 by Excerpta Medica, Inc.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/12/20 alle ore 05:29:32